Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical products globally and domestically. The Company’s product portfolio consists of tablet and capsules (general) solid oral dosage form and small volume parenteral- liquid injection vial and ampules. The Company’s products include Losartan Potassium Tablets USP 50 mg, Glimepiride Tablets USP 2 mg, Pantoprazole Tablets USP 40 mg, Methocarbamol Tablets USP 500 mg, Omeprazole Capsule IP 20 mg, Amlodipine besylate Tablets USP 5 mg, Ranitidine Tablets USP 150 mg, Ranitidine Tablets USP 300 mg, Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Atorvastatin Tablets USP 10mg, Sildenafil citrate Tablets BP 100 mg, Diclofenac Sodium Tablets BP 50 mg, Mebendazole Tablets USP 100 mg, Paracetamol Tablets BP 500 mg, Artemether 80 mg and Lumefantrine 480 mg Tablets, Clotrimazole Vaginal Tablets 100 mg and others.As of 25 May 2026, Shukra Pharmaceuticals Limited share price is ₹28.02. The stock opened at ₹29.01, compared to its previous close of ₹29.00. During today's trading session, Shukra Pharmaceuticals Limited share price moved in the range of ₹27.59 to ₹29.88, with an average price of ₹28.73 for the day. Looking at its last 52-week, the stock has touched a low of ₹27.59 and a high of ₹29.88.
The market capitalization of Shukra Pharmaceuticals Limited is ₹1,270 Crs, with a P/E ratio of 58.0 and a dividend yield of 0.00%.